Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers

SIMPLE SUMMARY: Immunotherapy has improved the outcomes of patients with advanced melanoma, although many patients will progress while on treatment. Preclinical animal models provide valuable insights into immunotherapy response or resistance and can be used to test novel treatment combinations. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Shklovskaya, Elena, Pedersen, Bernadette, Stewart, Ashleigh, Simpson, Jack O. G., Ming, Zizhen, Irvine, Mal, Scolyer, Richard A., Long, Georgina V., Rizos, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564179/
https://www.ncbi.nlm.nih.gov/pubmed/36230753
http://dx.doi.org/10.3390/cancers14194830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9564179/
https://www.ncbi.nlm.nih.gov/pubmed/36230753
http://dx.doi.org/10.3390/cancers14194830

Ejemplares similares